9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

Rib-X Pharmaceuticals
300 George Street
Suite 301
New Haven, CT 06511

Phone: 203-624-5606
Fax: 203-624-5627
Website: http://www.rib-x.com

General Information
Rib-X Pharmaceuticals is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company's drug discovery strategy exploits its proprietary high-resolution crystal structure on the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. The 50S is the target for many clinically valuable classes of antibiotics, including those used to treat both community-acquired and hospital pathogens. The company's integrated research approach combines state-of-the-art, proprietary computational analysis, x-ray crystallography, medicinal chemistry, microbiology and biochemistry, allowing for the rapid synthesis of new classes of antibiotics, which avoid typical antibiotic resistance mechanisms. Rib-X's iterative approach has rapidly yielded several distinctive chemical classes which it intends to bring into clinical testing. As their products enter Phase II studies, Rib-S will seek commercialization partnerships. The company is currently well-positioned to develop a pipeline of differentiable products that are expected to address distinct markets for the treatment of bacterial infections.

Other Information
Ownership: Private
CT Employees: 45